CDK-IN-18 (Compound EX.161) is an orally active, brain-penetrant and selective inhibitor of CDK2, CDK4, and CDK6. CDK-IN-18 inhibits the activity of cyclin-CDK complexes, blocks phosphorylation of the retinoblastoma protein (pRb), arresting the cell cycle transition from G1 to S phase. CDK-IN-18 is promising for research of cancers, such as breast cancer (especially hormone receptor-positive, HER2-negative type), lung cancer, and colorectal cancer[1][2].
Molecular Weight:
470.57
CAS Number:
[2531743-46-9]
Formula:
C26H30N8O
Target:
CDK
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
